My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Mark Erlander Biography and Net Worth

CEO of Cardiff Oncology

Dr. Erlander has served as a Director since June 2020 and has served as our Chief Executive Officer since May 2020, and formerly as the Chief Scientific Officer from March 2013 to May 2020. Previously, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviaraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994, Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications. Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.

What is Mark Erlander's net worth?: The estimated net worth of Mark Erlander is at least $62,426.55 as of November 25th, 2022. Dr. Erlander owns 24,481 shares of Cardiff Oncology stock worth more than $62,427 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Erlander may own. Additionally, Dr. Erlander receives an annual salary of $874,790.00 as CEO at Cardiff Oncology. Learn More about Mark Erlander's net worth.
How old is Mark Erlander?: Dr. Erlander is currently 64 years old. There are 3 older executives and no younger executives at Cardiff Oncology. The oldest executive at Cardiff Oncology is Dr. Fairooz Kabbinavar FACP, M.D., Chief Medical Officer, who is 67 years old. Learn More on Mark Erlander's age.
What is Mark Erlander's salary?: As the CEO of Cardiff Oncology, Inc., Dr. Erlander earns $874,790.00 per year. The highest earning executive at Cardiff Oncology is Dr. Tod Smeal Ph.D., Chief Scientific Officer?, who commands a salary of $2,690,000.00 per year. Learn More on Mark Erlander's salary.
How do I contact Mark Erlander?: The corporate mailing address for Dr. Erlander and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on Mark Erlander's contact information.
Has Mark Erlander been buying or selling shares of Cardiff Oncology?: Mark Erlander has not been actively trading shares of Cardiff Oncology within the last three months. Most recently, on Friday, November 25th, Mark Erlander bought 10,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.43 per share, with a total value of $14,300.00. Following the completion of the transaction, the chief executive officer now directly owns 24,481 shares of the company's stock, valued at $35,007.83. Learn More on Mark Erlander's trading history.
Who are Cardiff Oncology's active insiders?: Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.
Are insiders buying or selling shares of Cardiff Oncology?: In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $41,100.00. The most recent insider tranaction occured on December, 19th when Director Gary W Pace bought 30,000 shares worth more than $41,100.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.
Information on this page was last updated on 12/19/2023.

Mark Erlander Insider Trading History at Cardiff Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/25/2022	Buy	10,000	$1.43	$14,300.00	24,481
3/23/2021	Buy	965	$10.34	$9,978.10	14,481

Mark Erlander Buying and Selling Activity at Cardiff Oncology

Cardiff Oncology Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $2.55

$2.46

$2.58

50 Day Range

MA: $2.84

$2.46

$4.09

2 Week Range

Now: $2.55

$1.13

$6.42

Volume

177,864 shs

Average Volume

944,310 shs

Market Capitalization

$130.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Download Our Tesla Ebook For Free

From DTI | Ad

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Mark Erlander Biography and Net Worth

What is Mark Erlander's net worth?

How old is Mark Erlander?

What is Mark Erlander's salary?

How do I contact Mark Erlander?

Has Mark Erlander been buying or selling shares of Cardiff Oncology?

Who are Cardiff Oncology's active insiders?

Are insiders buying or selling shares of Cardiff Oncology?